With its S-4 now effective, Larkspur Health Acquisition today announced a Dec. 8 meeting for shareholders to vote on its proposed merger with ZyVersa Therapeutics in a deal valued at $109 million.
If approved, the combined company’s stock is expected to list on the Nasdaq under ticker symbol ZVSA.
Terms call for cash proceeds of approximately $77.67 million in Larkspur’s trust account (less any redemptions and expenses) and $8.5 million in PIPE commitments.
ZyVersa in September closed a bridge finance round of approximately $1.5 million from an offering of its Series A Convertible Preferred Stock, which will convert into ZyVersa common stock at deal closing.
ZyVersa is a clinical stage specialty biopharmaceutical company developing product candidates that address unmet medical needs in the areas of renal and inflammatory diseases. Read more.
